Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L. Lheureux S, et al. Among authors: briand m. Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25066666 Free article.
Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease.
Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A, Ngo-Van Do A, Nataf V, Batalla A, Gauduchon P, Talbot JN, Montravers F. Aide N, et al. Among authors: briand m. Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):396-405. doi: 10.1007/s00259-008-0984-x. Epub 2008 Dec 3. Eur J Nucl Med Mol Imaging. 2009. PMID: 19050878
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.
Aide N, Briand M, Bohn P, Dutoit S, Lasnon C, Chasle J, Rouvet J, Modzelewski R, Vela A, Deslandes E, Vera P, Poulain L, Carreiras F. Aide N, et al. Among authors: briand m. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):323-33. doi: 10.1007/s00259-010-1624-9. Epub 2010 Sep 30. Eur J Nucl Med Mol Imaging. 2011. PMID: 20882281
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Lheureux S, et al. Among authors: briand m. Int J Gynecol Cancer. 2012 Nov;22(9):1483-8. doi: 10.1097/IGC.0b013e31826d1438. Int J Gynecol Cancer. 2012. PMID: 23027040 Clinical Trial.
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N. Lheureux S, et al. Among authors: briand m. Transl Oncol. 2013 Oct 1;6(5):586-95. doi: 10.1593/tlo.13100. eCollection 2013. Transl Oncol. 2013. PMID: 24151539 Free PMC article.
164 results